Quality of the reporting of trials varied. 3 key findings →
Design: meta-analysis Participants: 3,353 Evidence: high
Full summary, score breakdown and related studies → Original source
Research
31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Faster alleviation of delirium and improved cognition justify good, comprehensive geriatric care for these patients although treatment produced no significant improvements in hard endpoints of prognosis. 4 key findings →
Participants: 87 Evidence: high
Full summary, score breakdown and related studies → Original source
Without validated cutoff scores, it is impossible to employ tests in a standardized fashion in front-line clinical settings. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
In these high-risk patients, antidepressant drug treatment does not seem to be related to suicide attempts and death in adults but might be related in children and adolescents. 4 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
A strategy of targeting type-specific BPSD may be beneficial, such as environmental stimulus control for DLB patients who are prone to have hallucinations, design of a pacing path for patients with FTD who need support for symptoms of wandering and emotional support for patients with VaD who are susceptible to depression. 1 key finding →
Participants: 137 Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings show an association between low circulating levels of one of the most important components of the human antioxidant system and the presence of frailty. 3 key findings →
Participants: 827 Evidence: low
Full summary, score breakdown and related studies → Original source
Standard validity indices showed that the LARS is sensitive and capable of distinguishing between apathy and depression. 2 key findings →
Participants: 159 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease is a progressive dementia with unknown etiology that affects a growing number of the aging population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
We provide evidence that poorly controlled diabetes and conditions associated with complications of diabetes are associated with an increased risk of falling in older people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Measures to prevent the morbidity associated with falls and fractures in bradykinetic rigid syndromes may be best directed at patients with the risk factors identified in this study. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In an inception cohort of 196 Olmsted County, Minnesota, residents with Parkinson's disease (PD) first recognized in 1976 to 1995, we tested whether the increased risk of bone fractures is associated with concomitant dementia. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The authors examined the relationship between cognition and gait velocity, performed with and without interference, in elderly participants. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Falls are common in Parkinson's disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Nutritional intake is often compromised in elderly, multimorbid patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Current research indicates that neurocognitive sequelae following critical illness are common, may be permanent, and are associated with impairments in daily function, decreased quality of life, and an inability to return to work. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The management of Parkinson's disease (PD) tends to focus on the presenting motor syndrome; yet, in the long term, nonmotor complications of the illness and complications of treatment become increasingly troublesome. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Energy intake is reduced in older individuals, with several lines of evidence suggesting that both physiological impairment of food intake regulation and non-physiological mechanisms are important. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In humans, age-related memory impairments begin in mid-life and cognitive weakening continues with advancing age. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The demonstration that isoflurane contributes to well-described mechanisms of Alzheimer's neuropathogenesis provides a plausible link between the acute effects of anesthesia, a well-described risk factor for delirium, and the more long-term sequelae of dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We describe solid-state nuclear magnetic resonance (NMR) measurements on fibrils formed by the 40-residue beta-amyloid peptide associated with Alzheimer's disease (Abeta(1-40)) that place constraints on the identity and symmetry of contacts between in-register, parallel beta-sheets in the fibrils. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events